Bicuspid Aortic Valve
Background
Bicuspid aortic valve (BAV) is the most common congenital cardiovascular malformation, characterized by the presence of two aortic valve leaflets instead of the typical three. [1] This condition affects approximately 0.5% to 2% of the general population. [1] The altered valve structure leads to abnormal blood flow dynamics and can predispose individuals to various cardiovascular complications throughout their lives.
Biological Basis
The biological basis of BAV is complex and originates from abnormal embryonic development of the aortic valve. [2] BAV exhibits high heritability and familial clustering, strongly indicating a significant genetic component. [3] Research has identified several genes implicated in BAV development, including NOTCH1 [4] GATA5 [5] fibrillin 1 (found in BAV patients both with and without Marfan syndrome) [6] and MATR3. [7] Additionally, recent studies highlight the role of defects in the exocyst-cilia machinery, associating primary cilia genes with the BAV phenotype. [1] The genetic landscape of BAV is heterogeneous, suggesting multiple pathways contribute to its etiology.
Clinical Relevance
Clinically, BAV is significant due to its association with a range of potentially life-threatening complications. [3] Common co-morbidities include ascending aortic dilation and calcific aortic valve stenosis (CAVS). [1] BAV can lead to altered hemodynamics, increasing the risk of aortic valve dysfunction, such as stenosis (narrowing) or regurgitation (leakage). Aortic stenosis, whether congenital or acquired, is a common cardiovascular condition, particularly prevalent in older adults. [8] Early detection and ongoing monitoring of BAV and its associated conditions are crucial for timely intervention and improved patient management.
Social Importance
Given its prevalence and the potential for severe complications, bicuspid aortic valve represents a substantial public health concern. Understanding its genetic underpinnings is vital for identifying individuals at risk, improving diagnostic accuracy, and developing targeted preventive or therapeutic strategies. [3] Ongoing genetic and molecular research aims to uncover additional causes and co-morbidities, ultimately improving the long-term outcomes and quality of life for affected individuals.
Methodological and Statistical Constraints
Genetic studies of bicuspid aortic valve (BAV) and related aortic phenotypes benefit from large datasets, such as the UK Biobank, which includes tens of thousands of participants with cardiac imaging data. [8] However, other investigations, particularly those focusing on specific case-control cohorts, have necessarily smaller sample sizes, for example, 565 Spanish cases and 484 controls in an exome-wide association study, or 473 BAV cases alongside controls from a surgical biobank. [3] Such variations in sample size can diminish statistical power, making it challenging to detect genetic effects of modest size or associations with rare genetic variants. [9] Furthermore, measurement errors inherent in phenotypic data collection can bias estimates towards the null hypothesis, potentially obscuring genuine genetic associations [9] while the application of genomic control adjustments in some analyses indicates the need to account for population stratification and relatedness. [10]
While multi-center studies and replication cohorts are employed to validate findings [1] the generalizability of specific genetic associations still benefits from broader, independent validation across diverse populations and methodologies. For instance, polygenic scores developed for aortic valve area, while validated in a separate subset of UK Biobank participants, demonstrated a relatively low predictive utility for clinically defined aortic valve disease (R²=0.006). [8] This suggests that the currently identified genetic factors explain only a small fraction of the phenotypic variance, highlighting the ongoing challenge in translating genetic discoveries into robust prognostic or diagnostic tools for complex cardiovascular conditions.
Phenotypic Characterization and Measurement Limitations
Many genetic analyses rely on imaging-derived measures that serve as proxies for complex valvular function or morphology, such as planimetric measures of aortic valve functional area obtained through automated cardiac MRI [8] or simplified 2D measurements of anatomical structures. [11] While these automated and proxy-based approaches are crucial for large-scale genetic investigations, they may not fully capture the intricate, three-dimensional anatomy of the aortic valve or subtle functional impairments. For example, M-mode echocardiography measurements of the aortic root are known to be less accurate and can underestimate aortic diameter when compared to more advanced 2-dimensional imaging [9] and even sophisticated automated estimation methods can introduce systematic errors or bias into the measurements. [11]
The definition and diagnosis of aortic valve conditions can also vary, stemming from a combination of clinical findings, including physical examination, auscultation, echocardiography, or functional data from invasive procedures. [8] The use of software-based MRI analysis or reliance on inpatient diagnosis codes, while practical for large biobanks, might introduce heterogeneity compared to a comprehensive, multi-modal clinical assessment. Additionally, studies often employ strict exclusion criteria, such as removing participants with large aortic diameters or a history of aortic aneurysm, dissection, or surgical procedures. [12] While necessary for focused analysis, these exclusions can inadvertently limit the spectrum of disease studied, potentially overlooking genetic contributions to more severe or advanced stages of BAV and associated aortopathy.
Generalizability and Unexplained Etiology
A significant limitation in the current understanding of BAV genetics is the predominant focus on populations of European or Caucasian ancestry across many large-scale genetic studies. [8] This narrow demographic focus restricts the generalizability of findings to other ancestral groups, potentially missing crucial genetic variants or environmental interactions that contribute to BAV prevalence and pathophysiology in diverse global populations. Furthermore, imaging measures derived from general population samples may reflect a complex interplay of both underlying pathological remodeling and environmental stress-induced changes [11] indicating that unmeasured environmental or gene-environment confounders could significantly influence phenotypic expression and complicate genetic interpretation.
Despite the identification of a few causal genes, the genetic basis for the vast majority of BAV cases remains largely unknown, pointing towards a complex genetic heterogeneity underlying this common congenital defect. [1] This "missing heritability" suggests that numerous genetic factors, potentially including rare variants, structural variations, or intricate polygenic interactions, have yet to be discovered and fully characterized. Moreover, correlation analyses between aortic valve area and other traits, while providing insights into shared genetic architecture, can be complicated by phenotypic and sample overlap between the traits being investigated and existing comorbidities within the study subjects [8] making it challenging to precisely distinguish direct genetic effects from pleiotropic influences or confounding factors.
Variants
Genetic variations play a significant role in the predisposition to and development of bicuspid aortic valve (BAV), a common congenital heart defect where the aortic valve has two leaflets instead of the usual three. The intricate process of heart and valve formation during embryonic development is highly sensitive to disruptions in gene function. Research into single nucleotide polymorphisms (SNPs) and their associated genes helps unravel the complex genetic architecture underlying BAV and related cardiovascular conditions . [3], [10]
Mucin 4 (MUC4) is a large glycoprotein found on the surface of epithelial cells, playing a role in cell signaling, cell adhesion, and protection of cell surfaces. These functions are critical during embryonic development, including the intricate processes involved in heart and valve formation. Variants such as rs2550262, rs2246901, and rs2293232 within the MUC4 gene could potentially alter the structure or expression of this mucin, thereby influencing cellular interactions or signaling pathways essential for proper aortic valve morphogenesis. While the specific impact of these MUC4 variants on BAV is an area of ongoing investigation, their presence may contribute to the diverse genetic landscape associated with congenital heart defects. [5]
Hemicentin 2 (HMCN2) encodes an extracellular matrix (ECM) protein, which is fundamental for maintaining the structural integrity of tissues and mediating cell-matrix interactions. In the developing heart, the ECM provides crucial scaffolding and signaling cues necessary for the proper formation and remodeling of cardiac structures, including the aortic valve leaflets. A variant like rs13294886 in HMCN2 could potentially affect the stability, assembly, or function of this ECM protein, leading to subtle or significant alterations in valve development. Such disruptions in ECM composition or organization are recognized as contributors to the pathogenesis of various connective tissue disorders and congenital heart anomalies, including BAV. [6]
LINC01708 is a long intergenic non-coding RNA (lincRNA), a class of RNA molecules known for their diverse roles in regulating gene expression, ranging from chromatin remodeling to transcriptional and post-transcriptional control. LincRNAs often act as critical regulators in developmental pathways, influencing the differentiation and function of various cell types. The variant rs7543130 within LINC01708 could potentially impact the stability, localization, or regulatory activity of this lincRNA, thereby altering the expression of target genes crucial for cardiac development. Given that genes like NOTCH1 and GATA5 are known to be involved in aortic valve disease, any lincRNA that regulates similar developmental pathways could contribute to the genetic susceptibility of conditions such as bicuspid aortic valve . [4], [5]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs2550262 rs2246901 rs2293232 |
MUC4 | bicuspid aortic valve |
| rs13294886 | HMCN2 | bicuspid aortic valve metabolite measurement |
| rs7543130 | LINC01708 | bulb of aorta size aortic stenosis bicuspid aortic valve atrial fibrillation aortic stenosis, aortic valve calcification |
Definition and Clinical Context of Bicuspid Aortic Valve
Bicuspid aortic valve (BAV) is the most prevalent congenital cardiovascular malformation, affecting approximately 2% of the general population. [3] This condition is precisely defined by the presence of an aortic valve with two functional cusps or leaflets, in contrast to the typical tri-leaflet structure of a healthy aortic valve. The atypical morphology of BAV is a significant clinical concern due to its strong association with various life-threatening complications, including aortic stenosis, aortic regurgitation, and ascending aortic dilation. [1] Understanding the precise definition and recognizing its prevalence are crucial for early diagnosis and management, given the potential for progressive valvular dysfunction and aortopathy.
The embryonic development of the bicuspid aortic valve involves complex processes that differentiate it from a normal tri-leaflet valve. [2] Key terms such as "aortic stenosis" (AS), "calcific aortic valve stenosis" (CAVS), and "ascending aortic dilation" are frequently used in conjunction with BAV, as these are common sequelae or co-occurring conditions. "Aortic root diameter" and "aortic distensibility" are also essential terms, referring to critical measurements used to assess the health and function of the aorta, particularly in patients with BAV who are at higher risk for aortopathy. [13] These related concepts emphasize that BAV is not merely a valvular anomaly but often part of a broader cardiovascular syndrome.
Morphological Classification and Diagnostic Imaging
The classification of bicuspid aortic valve morphology is critical for guiding clinical management and research. One comprehensive system utilizes cardiac MRI for a 4-stage categorization of BAV leaflet morphology, providing detailed anatomical insights. [14] Beyond structural classification, machine-learning and weakly supervised deep learning approaches have emerged for phenotypic classification of aortic valve malformations, offering advanced diagnostic capabilities. [15] These systems help differentiate subtypes of BAV and predict disease progression, moving towards more nuanced diagnostic frameworks beyond simple categorical presence or absence of the condition.
Diagnostic and measurement criteria for BAV and associated aortopathies rely heavily on advanced imaging modalities. Echocardiography is fundamental, involving comprehensive Doppler examinations to calculate transvalvular gradients using the modified Bernoulli equation and aortic valve area (AVA) using the continuity equation. [16] Cardiac MRI provides crucial planimetric measurements of the aortic valve area and allows for assessment of ascending aorta dimensions, including maximal (AAomax) and minimal (AAomin) sizes, from which ascending aorta distensibility can be calculated. [13] These measurements are often indexed to body surface area (BSA) to account for individual body size, ensuring standardized comparison across populations, with agreement typically assessed using the intraclass correlation coefficient (ICC). [13]
Genetic and Molecular Underpinnings
The genetic component of bicuspid aortic valve disease is significant, with high heritability and familial clustering rates supporting the search for underlying genetic factors. [3] Key genes implicated in BAV and associated aortopathies include NOTCH1, mutations in which are known to cause aortic valve disease. [4] Rare sequence variants in GATA5 have also been identified in individuals with BAV, and mutations in FBN1 (fibrillin 1 gene) have been linked to BAV even in the absence of Marfan syndrome. [5] These findings highlight a complex genetic architecture, involving both common and rare genetic variants, and underscore the role of specific molecular pathways, such as defects in the exocyst-cilia machinery, in the pathogenesis of BAV and aortic stenosis. [1]
Research criteria for identifying genetic associations often involve large-scale studies such as exome-wide association studies (EWAS) and genome-wide association studies (GWAS) to identify population-based genetic variation. [8] Transcriptome-wide association studies (TWAS) have further identified susceptibility genes like PALMD for calcific aortic valve stenosis, a common comorbidity. [16] These genetic analyses typically involve stringent quality control measures for genotyping data, including filtering for call rates, Hardy-Weinberg equilibrium, minor allele frequency, and exclusion of samples based on genotype completion rate or heterozygosity outliers, ensuring robust identification of genetic determinants. [16]
Clinical Presentation and Progression of Bicuspid Aortic Valve Disease
Bicuspid aortic valve (BAV) is a congenital heart malformation, affecting approximately 0.5–1.2% to 2% of the general population [1] . While individuals with BAV may remain asymptomatic for many years, its presence predisposes to various complications over time [1] . Common clinical presentations arise from secondary conditions such as ascending aortic dilation and calcific aortic valve stenosis (CAVS) [1] . The severity and timing of these complications exhibit significant inter-individual variability, with some patients maintaining stable valve function while others experience progressive valvular dysfunction or aortic enlargement requiring intervention [17] .
Diagnostic Imaging and Hemodynamic Assessment
The diagnosis and ongoing monitoring of BAV and its associated pathologies primarily rely on advanced cardiac imaging techniques. Two-dimensional echocardiography is routinely employed to assess aortic root dimensions at crucial anatomical landmarks, specifically the aortic annulus and sinuses of Valsalva, typically measured at end-diastole [18] . Cardiac magnetic resonance imaging (MRI) offers a comprehensive approach for categorizing BAV leaflet morphology and precisely quantifying aortic dimensions [8] . For the evaluation of calcific aortic valve stenosis, Doppler echocardiography is essential for calculating the transvalvular gradient using the modified Bernoulli equation and determining the aortic valve area via the continuity equation [16] . Objective measures such as aortic diameter and area are often indexed to body surface area (BSA) to standardize for overall body size, while aortic distensibility, calculated from the relative enlargement of the aorta during systole divided by the pulse pressure, provides an objective assessment of aortic wall elasticity [13] .
Genetic Predisposition and Phenotypic Heterogeneity
Bicuspid aortic valve disease exhibits notable phenotypic diversity and inter-individual variation, substantially influenced by a strong genetic component characterized by high heritability and familial clustering [1] . While specific causal genes such as NOTCH1 and GATA5 have been identified, the underlying genetic basis for the majority of BAV cases remains complex and heterogeneous [5] . Furthermore, mutations in FBN1 have been observed in BAV patients without a diagnosis of Marfan syndrome, and rare sequence variants in MCTP2 and MATR3 are associated with BAV and coarctation of the aorta [19] . Beyond the initial valve malformation, genetic factors also play a critical role in the progression of complications, with PALMD identified as a susceptibility gene for calcific aortic valve stenosis and defects in the Exocyst-Cilia Machinery implicated in the development of BAV and aortic stenosis [1] . These genetic insights are crucial for understanding the diagnostic and prognostic implications, enabling the identification of individuals at elevated risk for severe outcomes.
Genetic Predisposition and Heritability
Bicuspid aortic valve (BAV) is the most common congenital cardiovascular malformation, affecting approximately 0.5% to 2% of the general population. [1] Its high heritability and tendency for familial clustering strongly indicate a significant genetic component in its etiology. [3] Studies have identified both Mendelian forms, caused by mutations in single genes, and polygenic contributions, where multiple genetic variants collectively increase risk. For instance, mutations in NOTCH1 are known to cause aortic valve disease, including BAV, and rare sequence variants in GATA5 have been identified in individuals with the condition. [20]
Further genetic investigations have uncovered other specific genes and loci associated with BAV. Mutations in Fibrillin 1 have been identified in patients with BAV who do not have Marfan syndrome, suggesting a role in connective tissue integrity of the valve. [1] Additionally, a gene called MCTP2 is recognized as a dosage-sensitive gene critical for cardiac outflow tract development, and disruptions in MATR3 have been linked to BAV, often alongside other congenital heart defects like aortic coarctation and patent ductus arteriosus. [20] Genome-wide association studies (GWAS) have also highlighted specific single nucleotide polymorphisms (SNPs), such as rs71190365 near DLEU1, rs35991305 near CRADD, and a variant on chromosome 17 near GOSR2, as associated with aortic valve area, which in turn correlates with BAV risk. [8] These findings collectively underscore a complex genetic landscape involving both rare and common variants.
Developmental Origins and Ciliary Mechanisms
As a congenital defect, BAV arises from abnormalities during embryonic development, particularly concerning the formation of the aortic valve cusps. [1] The precise developmental pathways are intricate, but recent research points to the critical involvement of primary cilia and the exocyst-cilia machinery. Defects in this machinery have been identified as a cause of BAV disease, suggesting that proper ciliary function is essential for normal aortic valve morphogenesis. [1] These findings, derived from genome-wide association and replication studies, highlight a crucial genetic pathway that, when disrupted, can lead to the malformation of the aortic valve into a bicuspid rather than a tricuspid structure. [1]
Complex Genetic Architecture and Associated Conditions
The genetic basis for the majority of BAV cases remains largely unknown, indicating significant genetic heterogeneity and a complex interplay of multiple genes. [1] This complexity suggests that BAV is often a polygenic trait, where the combined effect of numerous genetic variants, each with a small effect, contributes to the overall risk. Beyond its primary manifestation, BAV is frequently associated with several comorbidities, most notably ascending aortic dilation and calcific aortic valve stenosis (CAVS). [1] Patients with BAV often present with these concurrent conditions, and genetic studies have revealed shared genetic comorbidities, implying common underlying genetic predispositions or pathways that increase susceptibility to both BAV and its associated aortic pathologies. [8]
Biological Background of Bicuspid Aortic Valve
Bicuspid aortic valve (BAV) is a congenital heart defect characterized by an aortic valve with two leaflets, or cusps, instead of the typical three. This structural abnormality affects a significant portion of the population, ranging from 0.5% to 1.2%. [1] BAV is not merely a structural anomaly but a complex condition with diverse genetic underpinnings and intricate developmental origins, often leading to progressive valve dysfunction and associated cardiovascular comorbidities such as ascending aortic dilation and calcific aortic valve stenosis. [1]
Embryonic Development and Morphogenesis
The formation of a bicuspid aortic valve originates from disrupted processes during early cardiac development, specifically affecting the morphogenesis of the aortic valve. [2] Normally, the heart valves, including the aortic valve, undergo precise cellular interactions and signaling events to form a tricuspid structure, which is essential for maintaining unidirectional blood flow. [11] In BAV, this intricate developmental program is altered, leading to the fusion of two cusps, most commonly the right and non-coronary cusps. [1] The proper development of the cardiac outflow tract, from which the aortic valve components arise, is a critical period, and genes such as MCTP2 are essential for this complex process. [19]
Genetic Basis and Regulatory Mechanisms
The etiology of bicuspid aortic valve is characterized by significant genetic heterogeneity, indicating that a variety of genetic factors can contribute to its manifestation. [1] Mutations in specific genes have been identified as causal, notably NOTCH1, which is a well-established cause of aortic valve disease. [4] Additionally, rare sequence variants within transcription factors like GATA5 have been found in individuals affected by BAV. [5] Beyond these, mutations in FBN1 (Fibrillin 1), a gene critical for the integrity of the extracellular matrix and typically associated with Marfan syndrome, have also been linked to BAV in patients without the full Marfan phenotype. [6] Disruptions in MATR3 have been associated with BAV, often co-occurring with other congenital heart defects such as aortic coarctation. [7] Genome-wide and exome-wide association studies have further broadened the understanding of BAV's genetic landscape, identifying associations with primary cilia genes and components of the exocyst complex. [1] For instance, a rare missense mutation in MYH6 has been associated with non-syndromic coarctation of the aorta, a condition that can overlap with BAV. [20] Furthermore, PALMD has been identified as a susceptibility gene for calcific aortic valve stenosis through transcriptome-wide association studies, shedding light on genetic predispositions to BAV comorbidities. [16]
Molecular and Cellular Pathways
A pivotal pathway implicated in BAV development and progression involves the primary cilia and the exocyst machinery, both of which are fundamental for normal heart development. [1] Primary cilia are specialized cellular organelles that serve as critical signaling hubs, and their proper function is indispensable during the morphogenesis of the aortic valve. [1] Genetic disruption of cilia, such as through the removal of IFT88, leads to a highly penetrant BAV phenotype. [1] The exocyst, a protein complex crucial for vesicle trafficking and ciliogenesis, functionally interacts with cilia-related proteins like Arl13b. [21] Defects in exocyst components, including EXOC5 or EXOC8, can result in impaired cilia formation, manifesting as shorter and less abundant cilia within the aortic valve, which correlates with an increased incidence of BAV. [1] This connection is further supported by the frequent occurrence of BAV and calcific aortic valve stenosis in patients with ciliopathies, which are syndromic diseases caused by mutations in primary cilia components. [1] While NOTCH1 signaling is known to be involved in aortic valve disease and relies on primary cilia for its proper function, studies on EXOC5 deficient valves did not show changes in NOTCH1 activation, suggesting a complex interplay or spatially distinct roles for cilia in various BAV etiologies. [1] Another significant pathway is the MAPK/ERK pathway, which contributes to valvular interstitial cell calcification. [22] Inhibition of this pathway can mitigate aortic valve disease processes, and its activation, evidenced by elevated pERK1/2, is frequently observed in calcified BAV models. [1] The integrity and organization of the extracellular matrix, modulated by signaling nodes like TGF-beta, are also essential for proper valve development and function. [23]
Pathophysiology and Disease Progression
Bicuspid aortic valve stands as the most common congenital heart defect and represents the most critical predictor for the subsequent development of aortic valve disease and aortic stenosis. [1] Beyond its initial congenital malformation, BAV is frequently associated with progressive comorbidities, notably ascending aortic dilation and calcific aortic valve stenosis (CAVS). [1] The process of calcific aortic valve disease is not merely a passive degenerative phenomenon but involves active biological mechanisms, including the dysregulation of cellular functions within the valve tissue. [24] For example, defects in the exocyst-cilia machinery, as demonstrated by Exoc5 deletion in mice, not only lead to BAV but also induce calcification of aortic valves, a process often accompanied by an increase in pERK1/2, a recognized marker of disease progression. [1] Specific biomolecules, such as Galectin-3, have also been identified as playing a role in the development of calcific aortic valve stenosis, underscoring the molecular complexity of this disease mechanism. [25] The abnormal structure of the bicuspid valve likely subjects it to altered hemodynamics and increased mechanical stress over time, contributing to these degenerative changes, ultimately leading to reduced flexibility, stenosis, and significant impairment of cardiac function. [11]
Genetic Determinants of Valve Morphogenesis
Bicuspid aortic valve (BAV) pathogenesis is strongly linked to genetic factors influencing early cardiac development, with mutations in key developmental genes known to cause aortic valve disease [4] For instance, rare sequence variants in GATA5 have been identified in individuals with BAV, underscoring the importance of specific transcription factors in orchestrating proper valve formation [5] The disruption of genes like MCTP2, which is dosage-sensitive and essential for cardiac outflow tract development, and MATR3, whose disruption is associated with BAV, further illustrates how precise genetic programming is required for normal valve morphogenesis [19]
Beyond direct structural or developmental genes, transcription factors like TBX5 are key regulators of heart development, and their activity is identified during human cardiac morphogenesis [26] The cooperative action of Smad4 and Gata4 also plays a significant role in cardiac valve development, signifying a complex regulatory network governing valve formation [11] A rare missense mutation in MYH6 has been associated with conditions like coarctation of the aorta, which frequently co-occurs with BAV, suggesting broader genetic influences on outflow tract anomalies [20] These genetic variations represent dysregulation at the transcriptional level, leading to altered gene expression profiles that impair the intricate processes of valve leaflet formation and septation during embryogenesis.
Ciliary Function and Cellular Trafficking
A critical pathway implicated in BAV involves the exocyst-cilia machinery, a complex responsible for directed vesicle trafficking and primary cilium formation, which plays a pivotal role in cellular signaling. Defects in this machinery directly cause BAV disease and aortic stenosis, underscoring its functional significance in valve health [1] Primary cilia are expressed during aortic valve development, and their genetic ablation, such as through the removal of IFT88, results in a highly penetrant BAV phenotype, demonstrating that intact ciliogenesis is indispensable for proper valve development [1] The exocyst, along with Arl13b, interacts synergistically to facilitate ciliogenesis, highlighting a systems-level integration of trafficking and cytoskeletal elements [21]
Further mechanistic insights reveal that disrupting the exocyst, for instance by deleting the key linker protein EXOC5, leads to severe cardiac phenotypes including shorter and less abundant cilia within the aortic valve, an increased incidence of BAV, and subsequent calcification [1] This indicates a direct link between impaired cellular trafficking, ciliary dysfunction, and disease progression. The ciliary targeting motif VxPx directs the assembly of a trafficking module through Arf4, illustrating the intricate molecular components and regulatory mechanisms that ensure proper ciliary function and, consequently, normal aortic valve development [27] Dysregulation of this pathway represents a crucial disease-relevant mechanism contributing to BAV and its progression to calcific aortic valve stenosis.
Key Signaling Pathways in Valve Development and Disease
Specific signaling pathways are fundamental to aortic valve development and disease progression. The NOTCH1 signaling pathway is prominently expressed on the aortic valve endocardium, and its mutations are a known cause of aortic valve disease, indicating its crucial role in cellular communication and fate determination during valve formation [1] Proper receptor activation and subsequent intracellular signaling cascades initiated by NOTCH1 are essential for guiding the differentiation and patterning of valve cells, and any dysregulation can lead to congenital malformations like BAV. Another critical cascade is the MAPK/ERK pathway, which is involved in valvular interstitial cell calcification, a common sequela of BAV [22]
The interplay between these pathways and other cellular processes forms a complex network. For example, deletion of EXOC5, which impairs ciliary function, leads to an elevation of pERK1/2, a marker of disease phenotype, demonstrating a direct crosstalk between ciliary defects and the activation of pro-calcific signaling [1] The inhibition of the MAPK-Erk pathway in vivo has been shown to attenuate aortic valve disease processes, positioning it as a potential therapeutic target by modulating intracellular signaling cascades and their downstream effects on gene expression and cellular behavior [28] Furthermore, myocardial-endocardial VEGF signaling is crucial for angiogenesis during coronary artery formation, a process that shares developmental links with valve development, suggesting broader systems-level integration of growth factor signaling in cardiac morphogenesis [29]
Extracellular Matrix Integrity and Calcific Progression
The integrity of the extracellular matrix (ECM) is paramount for normal aortic valve function, and its disruption is a key mechanism in BAV pathology and progression. Mutations in the fibrillin 1 gene have been identified in patients with BAV even in the absence of Marfan syndrome, highlighting the direct role of ECM structural components in maintaining valve leaflet architecture and flexibility [6] Defective fibrillin can lead to altered mechanical properties and tissue remodeling, setting the stage for subsequent pathological changes. The gene PALMD has been identified as a susceptibility gene for calcific aortic valve stenosis (CAVS), indicating its involvement in the structural and cellular processes that lead to valve stiffening and calcification [16]
Calcific aortic valve disease, for which BAV is the most important predictor, involves complex metabolic regulation and cellular processes leading to mineral deposition [1] The protein Galectin-3, for instance, has a recognized role in CAVS, suggesting its involvement in inflammation, fibrosis, and the active process of calcification within the valve tissue [25] This process involves the dysregulation of various cellular pathways that normally prevent mineralization, leading to a shift towards an osteogenic phenotype within valvular interstitial cells. These mechanisms represent critical disease-relevant pathways where aberrant protein modification and cellular responses contribute to the emergent property of valve calcification, significantly impacting valve function and patient outcomes.
Genetic Basis and Associated Conditions
Bicuspid aortic valve (BAV) is the most common congenital cardiovascular malformation, affecting approximately 2% of the general population. [3] Its high heritability and observed familial clustering strongly suggest a significant genetic component, driving interest in identifying specific risk or protective genetic factors. [3] Genetic studies have identified associations with various genes, including mutations in NOTCH1 and FBN1, the latter often seen in BAV patients without Marfan syndrome. [4] Additionally, sequence variants in GATA5 and disruption of MATR3 have been linked to BAV, often presenting with other congenital heart defects such as coarctation of the aorta and patent ductus arteriosus. [5]
The genetic predisposition to BAV is frequently intertwined with other cardiovascular anomalies, particularly ascending aortic dilation. Research indicates a shared genetic component between BAV and aortic dilation, emphasizing the importance of a comprehensive genetic evaluation in affected individuals and their families. [3] This genetic overlap contributes to an overlapping phenotype, where BAV patients are at increased risk for complications beyond valve dysfunction, including aortic aneurysm and dissection. Understanding these genetic associations is crucial for identifying individuals with complex presentations and for guiding screening strategies for related conditions.
Prognosis and Disease Progression
The presence of a bicuspid aortic valve carries significant prognostic implications, primarily due to its propensity for progressive dysfunction and complications over a patient's lifetime. BAV is a leading cause of aortic valve stenosis (AVS), with genetic factors playing a role in this progression. For instance, a polygenic risk score (PRS) for smaller aortic valve area, derived from cardiac magnetic resonance imaging (MRI) data, has been shown to predict an increased hazard ratio for developing AVS, independent of traditional risk factors like smoking and hypertension. [8] This highlights the long-term implications of BAV, where many individuals will eventually require intervention for severe stenosis or regurgitation, with a median follow-up time of 29 years observed in some studies. [8]
Beyond stenosis, BAV is associated with other adverse long-term outcomes, including the development of calcific aortic valve stenosis (CAVS) and coronary artery disease (CAD). [10] The identification of genetic loci, such as those near DLEU1, CRADD, and GOSR2, associated with aortic valve area, further refines our understanding of disease progression and offers potential targets for predicting who might develop significant valve disease. [8] These genetic insights contribute to predicting individual disease trajectories and informing the timing of monitoring and potential interventions.
Clinical Assessment and Risk Stratification
Effective clinical management of bicuspid aortic valve necessitates robust diagnostic and monitoring strategies to accurately assess valve morphology, function, and associated aortic pathologies. Cardiac imaging, particularly cardiac MRI, is a valuable tool for detailed assessment of aortic valve area and morphology, allowing for a comprehensive four-stage categorization of leaflet types. [8] These imaging-derived parameters, along with genetic data, are integral for personalized risk assessment, helping clinicians identify individuals at higher risk for complications such as progressive aortic stenosis or ascending aortic dilation. [13]
Risk stratification in BAV patients is increasingly incorporating genetic insights to move towards personalized medicine approaches. Exome-wide association studies have sought to identify genetic variants linked to BAV and its complications, providing a foundation for identifying high-risk individuals even before overt symptoms appear. [3] The use of polygenic risk scores derived from genome-wide association studies can further enhance the prediction of future aortic valve stenosis, allowing for earlier and more targeted prevention strategies and surveillance protocols. [8] This integrated approach, combining advanced imaging with genetic risk assessment, enables clinicians to tailor monitoring frequency and intervention timing, ultimately improving long-term patient care.
Frequently Asked Questions About Bicuspid Aortic Valve
These questions address the most important and specific aspects of bicuspid aortic valve based on current genetic research.
1. My dad has this valve issue. Will I get it too?
It's quite possible. Bicuspid aortic valve (BAV) often runs in families and has a significant genetic component, meaning it's highly heritable. While not everyone with a family history will develop it, having a close relative like your dad with BAV does increase your personal risk. This is why doctors often recommend screening for family members.
2. Can I pass this valve condition to my children?
Yes, there's a strong chance you could pass it on due to its high heritability and familial clustering. BAV is linked to specific genes, and if you carry one of these genetic variations, your children could inherit it. Discussing your family history with a doctor is important for their potential future health screenings.
3. I feel totally healthy. Could I still have this valve problem?
Absolutely. Many people with bicuspid aortic valve (BAV) don't experience symptoms for years, or even decades. The condition is a structural difference, having two valve leaflets instead of three, and while it's present from birth, complications might only appear later in life. That's why early detection through imaging is so crucial.
4. Why do some people get severe valve issues but others don't?
The severity of bicuspid aortic valve (BAV) complications can vary greatly, even among those with the condition. This difference is partly due to the complex genetic landscape, where multiple genetic pathways contribute to its development and how it progresses. Some individuals might be more prone to issues like aortic dilation or calcific aortic valve stenosis due to their specific genetic makeup.
5. Is there a genetic test to see if I'm at risk?
Yes, genetic research has identified several genes linked to bicuspid aortic valve (BAV), such as NOTCH1, GATA5, fibrillin 1, and MATR3. While genetic testing can identify some of these specific variants, the genetics of BAV are complex and heterogeneous. A positive test might indicate risk, but a negative one doesn't completely rule it out, as not all genetic causes are known.
6. Can regular exercise prevent problems with my valve?
Regular exercise is beneficial for general cardiovascular health, but it cannot prevent the development of a bicuspid aortic valve (BAV) itself, as it originates from abnormal embryonic development. While it won't change the valve's structure, maintaining a healthy lifestyle can help manage overall heart health, which is important given BAV can predispose you to various complications.
7. Does this valve condition usually get worse with age?
Yes, individuals with bicuspid aortic valve (BAV) are predisposed to various cardiovascular complications throughout their lives, and these often become more apparent or severe with age. Conditions like ascending aortic dilation and calcific aortic valve stenosis (CAVS) are common co-morbidities, with CAVS being particularly prevalent in older adults.
8. Why is finding this valve issue early so important for me?
Early detection of bicuspid aortic valve (BAV) is crucial because it allows for ongoing monitoring and timely intervention if complications arise. Since BAV can lead to serious issues like aortic stenosis, regurgitation, or aortic dilation, knowing you have it means doctors can watch for changes and step in before problems become life-threatening.
9. My sibling has it, but I seem fine. Why the difference?
Even within families, the expression of bicuspid aortic valve (BAV) can vary. While BAV has a strong genetic component and familial clustering, its genetic landscape is heterogeneous, meaning multiple genes and pathways are involved. This complexity, combined with other genetic or environmental factors, can explain why one sibling might be affected and another appears healthy.
10. Is it true this valve problem starts when I'm a baby?
Yes, that's absolutely true. Bicuspid aortic valve (BAV) is a congenital cardiovascular malformation, meaning it's present at birth. It originates from abnormal embryonic development of the aortic valve, where it forms with two leaflets instead of the usual three during fetal development.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Fulmer D, et al. "Defects in the Exocyst-Cilia Machinery Cause Bicuspid Aortic Valve Disease and Aortic Stenosis." Circulation, vol. 140, no. 15, 8 Oct. 2019, pp. 1252-1266. PMID: 31387361.
[2] Martin PS, et al. "Embryonic Development of the Bicuspid Aortic Valve." J Cardiovasc Dev Dis, vol. 2, no. 4, Oct. 2015, pp. 248-72. PMID: 28529942.
[3] Gago-Diaz M, et al. "The genetic component of bicuspid aortic valve and aortic dilation. An exome-wide association study." J Mol Cell Cardiol, vol. 102, Jan. 2017, pp. 3-9. PMID: 27894865.
[4] Garg V, et al. "Mutations in NOTCH1 cause aortic valve disease." Nature, vol. 437, no. 7056, 8 Sept. 2005, pp. 270-4. PMID: 16121175.
[5] Bonachea EM, et al. "Rare GATA5 sequence variants identified in individuals with bicuspid aortic valve." Pediatr Res, vol. 76, no. 2, Aug. 2014, pp. 211-6. PMID: 24796370.
[6] Pepe G, et al. "Identification of fibrillin 1 gene mutations in patients with bicuspid aortic valve (BAV) without Marfan syndrome." BMC Med Genet, vol. 15, 24 Feb. 2014, p. 23. PMID: 24564502.
[7] Quintero-Rivera F. et al. "MATR3 disruption in human and mouse associated with bicuspid aortic valve, aortic coarctation and patent ductus arteriosus." Hum Mol Genet, vol. 24, 2015, pp. 2375–2389.
[8] Cordova-Palomera A, et al. "Cardiac Imaging of Aortic Valve Area from 34,287 UK Biobank Participants Reveal Novel Genetic Associations and Shared Genetic Comorbidity with Multiple Disease Phenotypes." Circ Genom Precis Med, vol. 13, no. 6, Dec. 2020, pp. e003058. PMID: 33125279.
[9] Vasan, RS et al. "Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data." JAMA, vol. 302, no. 2, 2009, pp. 168-178.
[10] Helgadottir A, et al. "Genome-wide analysis yields new loci associating with aortic valve stenosis." Nat Commun, vol. 9, no. 1, 6 Mar. 2018, p. 953. PMID: 29511194.
[11] Yu M. et al. "Genome-Wide Association Meta-Analysis Supports Genes Involved in Valve and Cardiac Development to Associate With Mitral Valve Prolapse." Circ Genom Precis Med, vol. 14, no. 5, 2021, p. e003260.
[12] Pirruccello, JP et al. "Deep learning enables genetic analysis of the human thoracic aorta." Nature Genetics, vol. 53, no. 12, 2021, pp. 1656-1665.
[13] Benjamins JW, et al. "Genomic insights in ascending aortic size and distensibility." EBioMedicine, vol. 75, Jan. 2022, p. 103775. PMID: 34968759.
[14] Murphy IG, et al. "Comprehensive 4-stage categorization of bicuspid aortic valve leaflet morphology by cardiac MRI." J Cardiovasc Magn Reson, vol. 19, no. 1, 15 Mar. 2017, p. 24. PMID: 28299607.
[15] Fries JA, et al. "Weakly supervised classification of aortic valve malformations using deep learning." J Am Coll Cardiol, vol. 74, no. 2, 16 July 2019, pp. 238-249. PMID: 31308376.
[16] Theriault S, et al. "A transcriptome-wide association study identifies PALMD as a susceptibility gene for calcific aortic valve stenosis." Nat Commun, vol. 9, no. 1, 6 Mar. 2018, p. 954. PMID: 29511167.
[17] Aubart M, et al. "Association of modifiers and other genetic factors explain Marfan syndrome clinical variability." Eur J Hum Genet, vol. 26, no. 11, Nov. 2018, pp. 1656-1665. PMID: 30087447.
[18] Wineinger, Nicole E., et al. "Genome-wide joint SNP and CNV analysis of aortic root diameter in African Americans: the HyperGEN study." BMC Med Genomics, vol. 4, 2011, p. 4.
[19] Lalani SR. et al. "MCTP2 is a dosage-sensitive gene required for cardiac outflow tract development." Hum Mol Genet, vol. 22, 2013, pp. 4339–4348.
[20] Bjornsson T. et al. "A rare missense mutation in MYH6 associates with non-syndromic coarctation of the aorta." Eur Heart J, vol. 39, no. 19, 2018, pp. 1655–1662.
[21] Seixas C. et al. "Arl13b and the exocyst interact synergistically in ciliogenesis." Mol Biol Cell, vol. 27, 2016, pp. 308–320.
[22] Gu X and Masters KS. "Role of the MAPK/ERK pathway in valvular interstitial cell calcification." Am J Physiol Heart Circ Physiol, vol. 296, 2009, pp. H1748–H1757.
[23] Azhar, M. et al. "Transforming growth factor beta in cardiovascular development and function." Cytokine Growth Factor. Rev., vol. 14, no. 5, 2003, pp. 391–407.
[24] Rajamannan NM, Gersh B and Bonow RO. "Calcific aortic stenosis: from bench to the bedside--emerging clinical and cellular concepts." Heart, vol. 89, no. 7, 2003, pp. 801–805.
[25] Sadaba JR. et al. "Role for Galectin-3 in Calcific Aortic Valve Stenosis." J Am Heart Assoc, vol. 5, no. 11, 2016, p. e004360.
[26] Hatcher, C. J. et al. "Identification and localization of TBX5 transcription factor during human cardiac morphogenesis." Dev Dyn, 2000.
[27] Mazelova, J. et al. "Ciliary targeting motif VxPx directs assembly of a trafficking module through Arf4." EMBO J, 2009.
[28] Munjal C. et al. "Inhibition of MAPK-Erk pathway in vivo attenuates aortic valve disease processes in Emilin1-deficient mouse model." Physiol Rep, vol. 5, no. 4, 2017, p. e13152.
[29] Wu, B. et al. "Endocardial cells form the coronary arteries by angiogenesis through myocardial-endocardial VEGF signaling." Cell, 2012.